Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin

Leukemia

Volumn 27, Issue 1, 2013, Pages 233-235

  Kurimoto, M ^a   Matsuoka, H ^b   Hanaoka, N ^a   Uneda, S ^a   Murayama, T ^c   Sonoki, T ^a   Nakakuma, H ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HYOGO CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CALICHEAMICIN; CD33 ANTIGEN; DNA METHYLTRANSFERASE; GEMTUZUMAB OZOGAMICIN; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; DRUG CYTOTOXICITY; INTERNALIZATION; LETTER; LEUKEMIA CELL; LOW DRUG DOSE; LYSOSOME; MONOTHERAPY; PRIORITY JOURNAL; TARGET CELL;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZACITIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA; NEOPLASM RECURRENCE, LOCAL; TUMOR CELLS, CULTURED;

EID: 84873569141     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.178     Document Type: Letter

References (14)

1. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003; 98: 2095-2104.
2. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197-3204.
3. Leone G, Teofili L, Voso MT, Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002; 87: 1324-1341.
4. Lehmann U, Brakensiek K, Kreipe H. Role of epigenetic changes in hematological malignancies. Ann Hematol 2004; 83: 137-152.
5. Graubert T, Walter MJ. Genetics of myelodysplastic syndromes: new insights. Hematology Am Soc Hematol Educ Program 2011; 2011: 543-549.
6. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wijermans P et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-20-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957-2964.
7. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009; 15: 3938-3946.
8. Tang R, Faussat AM, Majdak P, Perrot JY, Chaoui D, Legrand O et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004; 18: 1246-1251.
9. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-76.
10. ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicininduced apoptosis in acute myeloid leukemic cells. Leukemia 2007; 21: 248-252.
11. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003; 102: 1466-1473.
12. Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L et al. Preliminary results of southwest oncology group study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009; 114: (ASH Abstract, 790).
13. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29: 369-377.
14. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie J-N. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379: 1508-1516.